Source link : https://newshealth.biz/health-news/novel-oral-agent-for-esr1-mutated-breast-cancer-boosts-pfs-in-second-line/
(MedPage Today) — CHICAGO — The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115827 Author : Publish date : 2025-05-31 12:00:00 Copyright for syndicated content belongs to the linked Source.
The post Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8